一种以芘为基础的HDAC抑制剂，用于乳腺癌的双作用治疗

IF 4.3 2区化学 Q2 CHEMISTRY, MULTIDISCIPLINARY

Chemical Communications Pub Date : 2025-06-05 DOI:10.1039/d5cc01722j

Qizhang Li, Xing Lu, Yuanli Yang, Tianyu Li, Xuehua Chen, Rongmiao Yuan, Xin Ding, Silong Zhang, Huan He

引用次数: 0

摘要

在这里，我们报道了PySAHA，一种多功能HDAC抑制剂，它可以通过疏水标记机制独特地降解细胞内的HDAC，并且还具有光动力治疗活性。这些双重功能的协同相互作用产生了强大的抗乳腺癌功效。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

A pyrene-based HDAC inhibitor for dual-action therapy of breast cancer

查看原文本刊更多论文

A pyrene-based HDAC inhibitor for dual-action therapy of breast cancer

Here we report PySAHA, a multifunctional HDAC inhibitor, which can uniquely degrade HDACs within cells via a hydrophobic tagging mechanism, and also possesses photodynamic therapeutic activity. The synergistic interplay of these dual functionalities results in potent anti-breast cancer efficacy.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Chemical Communications 化学-化学综合

CiteScore

8.60

自引率

4.10%

发文量

2705

审稿时长

1.4 months

期刊介绍： ChemComm (Chemical Communications) is renowned as the fastest publisher of articles providing information on new avenues of research, drawn from all the world''s major areas of chemical research.